Restore Medical’s ContraBand Implant Evaluated to Treat Chronic Left Ventricular Failure in FIH Trial

December 1, 2021—Restore Medical Ltd., an Israel-based company, announced preliminary results of the first-in-human (FIH) clinical trial of the company’s ContraBand implant for patients with congestive heart failure. The minimally invasive, catheter-delivered device is used to treat patients with chronic left ventricular failure.

Restore Medical reported that the initial implantation procedures with the ContraBand were successfully performed at ZNA Middelheim Hospital in Antwerp, Belgium, followed by Kaplan Medical Center in Rehovot, Israel.

According to the company, the ContraBand is expected to relieve symptoms and improve patients’ quality of life by causing the healthy right ventricle to assist the failing left ventricle. The function of the implant is fully reversible even long after the procedure.